three-dose Covid-19 vaccine ZyCoV-D, the company said in a statement on Friday. As per a regulatory filing, the Shilpa Medicare has “entered into a definitive agreement with Cadila Healthcare Ltd (CHL) for production-supply of the ZyCov-D vaccine drug substance from its integrated Biologics R&D cum Manufacturing center at Dharwad, Karnataka." The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties, it added. "The company will transfer the ZyCoV-D technology to Shilpa Biologicals Pvt Ltd (SBPL).
Under the agreement, SBPL will be responsible for the manufacture of the drug substance of the vaccine, while the company is responsible for filling/packaging /distribution /marketing of the